Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) – Cantor Fitzgerald issued their FY2018 earnings estimates for Progenics Pharmaceuticals in a note issued to investors on Sunday. Cantor Fitzgerald analyst M. Goldstein anticipates that the biotechnology company will post earnings of ($0.51) per share for the year. Cantor Fitzgerald has a “Buy” rating and a $15.00 price target on the stock. Cantor Fitzgerald also issued estimates for Progenics Pharmaceuticals’ FY2019 earnings at $0.06 EPS.
Other research analysts have also issued reports about the company. Zacks Investment Research lowered Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday. BidaskClub raised Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 14th. Finally, ValuEngine raised Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, December 7th. Two research analysts have rated the stock with a sell rating, three have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Progenics Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $12.35.
Progenics Pharmaceuticals (NASDAQ:PGNX) last announced its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.21) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.21). The business had revenue of $3.90 million for the quarter, compared to analyst estimates of $3.18 million. Progenics Pharmaceuticals had a negative return on equity of 87.30% and a negative net margin of 436.08%. The company’s revenue was down 15.2% on a year-over-year basis. During the same period in the prior year, the company earned ($0.10) earnings per share.
Institutional investors and hedge funds have recently modified their holdings of the business. KBC Group NV grew its holdings in Progenics Pharmaceuticals by 10.2% in the third quarter. KBC Group NV now owns 234,777 shares of the biotechnology company’s stock valued at $1,728,000 after purchasing an additional 21,791 shares during the period. Los Angeles Capital Management & Equity Research Inc. grew its holdings in Progenics Pharmaceuticals by 457.2% in the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 88,980 shares of the biotechnology company’s stock valued at $655,000 after purchasing an additional 73,010 shares during the period. Cadence Capital Management LLC grew its holdings in Progenics Pharmaceuticals by 7.8% in the fourth quarter. Cadence Capital Management LLC now owns 260,046 shares of the biotechnology company’s stock valued at $1,547,000 after purchasing an additional 18,770 shares during the period. Gradient Investments LLC grew its holdings in Progenics Pharmaceuticals by 36.0% in the fourth quarter. Gradient Investments LLC now owns 74,192 shares of the biotechnology company’s stock valued at $441,000 after purchasing an additional 19,630 shares during the period. Finally, Hikari Power Ltd acquired a new stake in Progenics Pharmaceuticals in the third quarter valued at approximately $1,472,000. 86.51% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This article was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2018/03/14/equities-analysts-set-expectations-for-progenics-pharmaceuticals-inc-s-fy2018-earnings-pgnx.html.
Progenics Pharmaceuticals Company Profile
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.